|
|
Дата |
|---|
| 18.11.2026 |
| 17.11.2026 |
| 16.11.2026 |
| 13.11.2026 |
| 12.11.2026 |
| 11.11.2026 |
| 10.11.2026 |
| 09.11.2026 |
| 06.11.2026 |
| 05.11.2026 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
|---|---|---|---|---|---|---|---|
|
|
|
0.735
|
0.735
|
0.815
|
0.81
|
|
|
|
|
|
|
|
0.705
|
0.68
|
0.735
|
0.735
|
|
|
|
|
|
|
|
0.755
|
0.70
|
0.775
|
0.715
|
|
|
3 312.00
|
|
|
|
|
0.74
|
0.715
|
0.755
|
0.75
|
|
|
|
|
|
|
|
0.765
|
0.735
|
0.785
|
0.74
|
|
|
|
|
|
|
|
0.76
|
0.76
|
0.805
|
0.78
|
|
|
|
|
|
|
|
0.80
|
0.765
|
0.805
|
0.765
|
|
|
|
|
|
|
|
0.805
|
0.795
|
0.825
|
0.805
|
|
|
|
|
|
|
|
0.79
|
0.785
|
0.81
|
0.805
|
|
|
|
|
|
|
|
0.885
|
0.805
|
0.905
|
0.805
|
|
|
|
|
Novabridge Biosciences is a global biotechnology platform company. The Company combines deep business development expertise with agile translational clinical development to identify, accelerate, and advance breakthrough assets. Its differentiated pipeline includes givastomig, a bispecific antibody (Claudin 18.2 x 4-1BB), and VIS-101, a bifunctional biologic, targeting VEGF-A and ANG2. Givastomig conditionally activates T cells via the 4-1BB signaling pathway in the tumor microenvironment where Claudin 18.2 is expressed. Givastomig is being developed to treat Claudin 18.2-positive gastric cancer and other gastrointestinal malignancies.
VIS-101 targets VEGF-A and ANG-2 to provide more potent and durable treatment benefits for patients with wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). VIS-101 is completing a large, randomized, dose-ranging Phase 2 study for wet AMD.
Показать все Скрыть| 20.08.2026 |
|
| 28.08.2024 |
|